Literature DB >> 3874471

Vaccinia virus proteins on the plasma membranes of infected cells. II. Expression of viral antigens and killing of infected cells by vaccinia virus-specific cytotoxic T cells.

V R Mallon, E A Domber, J A Holowczak.   

Abstract

Evidence is presented that virion-derived antigens as well as viral antigens expressed on cell surfaces after infection, may participate in the formation of "target-antigen complexes" (TACs) which render vaccinia virus-infected cells susceptible to recognition and killing by syngeneic, vaccinia virus-specific cytotoxic T cells (VV-CTLs). By employing L cells infected with trypsin-treated and untreated virions, evidence was obtained that proteins with molecular weights of 32K and 37K may be among the virion-derived antigens which participate in TAC formation. Following virus infection, a sequential expression of virus-specified antigens on the plasma membrane of infected cells could be detected. At 1 hr p.i., polypeptides with molecular weights of 48K-50K and 36K-37K were present on infected cell surfaces; by 2 hr p.i., polypeptides with molecular weights of 48K-50K, 42K-44K, 36K-37K, 29K-30K, and 16K-17K were detected on plasma membranes. As measured by in vitro, 51Cr-release assays, vaccinia virus-infected L cells were completely susceptible to lysis by VV-CTLs (greater than or equal to 50% measured specific lysis) when (a) "early" but not late viral functions were expressed as measured with virus-infected cells which had been treated with hydroxyurea (5 X 10(-3) M) to block DNA replication or (b) when active protein synthesis was allowed to proceed for 90 min postadsorption and the infected cells were then treated with cycloheximide (100 micrograms/ml) to block further protein synthesis. Under these experimental conditions, polypeptides with molecular weights of 58K, 48K-50K, 42K, 36K-37K, 34K, 32K-33K, 27K-29K, and 16K-17K were expressed on the plasma membranes of vaccinia virus-infected cells but not uninfected cells. Whether each of the virion-derived and (or) virus-encoded polypeptides can associate with Class I, major histocompatibility antigens on the surfaces of virus-infected cells to form a primary or cross-reacting TAC recognized by VV-CTLs remains to be investigated.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3874471     DOI: 10.1016/0042-6822(85)90197-7

Source DB:  PubMed          Journal:  Virology        ISSN: 0042-6822            Impact factor:   3.616


  10 in total

1.  Rotavirus-specific protein synthesis is not necessary for recognition of infected cells by virus-specific cytotoxic T lymphocytes.

Authors:  P A Offit; H B Greenberg; K I Dudzik
Journal:  J Virol       Date:  1989-08       Impact factor: 5.103

2.  A 14,000-Mr envelope protein of vaccinia virus is involved in cell fusion and forms covalently linked trimers.

Authors:  J F Rodriguez; E Paez; M Esteban
Journal:  J Virol       Date:  1987-02       Impact factor: 5.103

3.  Structural and functional studies of a 39,000-Mr immunodominant protein of vaccinia virus.

Authors:  J S Maa; M Esteban
Journal:  J Virol       Date:  1987-12       Impact factor: 5.103

4.  Langerhans cells in vaccinia virus infection in mouse skin.

Authors:  Y Becker; E Sprecher
Journal:  Arch Virol       Date:  1989       Impact factor: 2.574

5.  Immunotherapy of the rat 13762SC mammary adenocarcinoma by vaccinia virus augmentation of tumor immunity.

Authors:  T P Archer; P Bretscher; B Ziola
Journal:  Clin Exp Metastasis       Date:  1990 Nov-Dec       Impact factor: 5.150

6.  Evidence that treatment with vaccinia melanoma cell lysates (VMCL) may improve survival of patients with stage II melanoma. Treatment of stage II melanoma with viral lysates.

Authors:  P Hersey; A Edwards; A Coates; H Shaw; W McCarthy; G Milton
Journal:  Cancer Immunol Immunother       Date:  1987       Impact factor: 6.968

7.  Infection of DBA/2 or C3H/HeJ mice by intraperitoneal injection of vaccinia virus elicits activated macrophages, cytolytic and cytostatic for S91-melanoma tumor cells.

Authors:  R J Natuk; J A Byrne; J A Holowczak
Journal:  Cancer Immunol Immunother       Date:  1986       Impact factor: 6.968

8.  Vaccinia virus-specific CD8+ cytotoxic T lymphocytes in humans.

Authors:  W E Demkowicz; F A Ennis
Journal:  J Virol       Date:  1993-03       Impact factor: 5.103

9.  Herpes simplex virus type 1-specific cytotoxic T lymphocytes recognize virus nonstructural proteins.

Authors:  S Martin; R J Courtney; G Fowler; B T Rouse
Journal:  J Virol       Date:  1988-07       Impact factor: 5.103

10.  The immune response to vaccinia virus infection in mice: analysis of the role of antibody.

Authors:  F J Novembre; K Raska; J A Holowczak
Journal:  Arch Virol       Date:  1989       Impact factor: 2.574

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.